shengnuo biotechnology will see double growth in revenue and net profit in 2021 and enter the cosmetics business

The 2021 annual report released by shengnuo biotechnology on April 26 showed that the operating income was 387 million yuan

a year-on-year increase of 2.05%; the net profit was 61.2528 million yuan, a year-on-year increase of 2.09%; the net profit after deduction was 58.100 million Yuan, a year-on-year increase of 12.38%.

In 2021, the company’s business will maintain a stable development trend as the CDMO projects of many of the company’s customers enter the clinical trial stage, and the preparations of overseas customers of APIs are approved for listing. At present, the company has gained a high reputation and recognition in the field of peptide drug R&D and production.

For the pharmaceutical research and customized production services of more than 10 projects, 1 innovative peptide drug has been approved and entered the commercialization stage, and another 10 innovative peptide drugs have entered the clinical trial stage. During the reporting period, among the R&D and R&D projects that the company participated in, there were 4 applications for consistency evaluation, and 1 item was approved for registration.

As of the disclosure date of the report, shengnuo biotechnology has 15 varieties of polypeptide APIs independently developed.

In the domestic market, the company has obtained production approvals or activation filings for 9 varieties of polypeptide APIs, among which enfuvirtide and carbetocin are the first domestic imitation varieties; in foreign markets, the company’s 9 varieties including liraglutide have obtained U.S. DMF filing, of which 8 varieties are in the active state, and can be cited by preparation manufacturers for declaration.

In 2021, shengnuo biotechnology also obtained 7 invention patents. Up to now, the company and its subsidiaries have 32 invention patents (2 of which have obtained international patents at the same time) and a large number of non-patented technologies.

The annual report also shows that peptide drugs have also made some progress in the past two years in terms of anti-coronavirus.

During the reporting period, relying on the existing technology platform, the company provided pharmaceutical research services for two innovative drugs for COVID-19 treatment from different customers, one of which has obtained clinical trial approval and is providing clinical sample production services for it.

It is worth mentioning that shengnuo biotechnology disclosed for the first time in its annual report an “outbound investment” matter: Chengdu Shengrong Netac, a wholly-owned subsidiary of the company, subscribed for a new registration of 4.9 million yuan from Guangzhou Shengjing Shangmei Biotechnology Co., Ltd. for 2,450 yuan. Capital, accounting for 49% of the total share capital of Guangzhou Shengjing after the capital increase.

The capital increase agreement has been signed and the capital contribution will be completed on March 11, 2022. According to public information, Guangzhou Shengjing is committed to providing customers with a full range of peptide medical beauty products and services, and has its own brand of products and formulas. In the early stage, shengnuo biotechnology mainly provided raw materials for the company.

It can also be seen from the annual report that the two wholly-owned subsidiaries of shengnuo biotechnologytech, Shengnuo biotechnology Peptide and Meishan Huilong, are mainly engaged in the “R&D, production, sales, technical consultation and transfer of multiple cosmetic raw materials and cosmetics”.

The first quarterly report disclosed by shengnuo biotechnology at the same time shows that the company achieved operating income of 80.7448 million yuan from January to March this year, a year-on-year decrease of 13.44%; net profit was 14.2929 million yuan, a year-on-year increase of 22.64%. As of the end of the first quarter, the number of shareholders of the company was 6,406, a decrease of 1,127 or 14.96% from December 31, 2021.